Literature DB >> 26010683

MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Gustavo Tapia1, Maria-Joao Baptista2, Ana-Maria Muñoz-Marmol1, Ayman Gaafar3, Maria Puente-Pomposo4, Olga Garcia2, Ruth Marginet-Flinch1, Carolina Sanz1, Jose-Tomas Navarro2, Juan-Manuel Sancho2, Josep-Maria Ribera2, Aurelio Ariza1, Jose-Luis Mate1.   

Abstract

MYC and BCL2 gene translocations and protein expression have recently demonstrated to be of prognostic significance in systemic diffuse large B-cell lymphoma (DLBCL). However, their role in primary central nervous system DLBCL (CNS-DLBCL) prognosis has been scarcely analyzed. We studied the immunophenotype, the status of the MYC, BCL2, and BCL6 genes and the clinical features of a series of 42 CNS-DLBCL and evaluated their prognostic significance. We found high MYC protein expression in 43% of cases, and this was associated with lower overall survival (OS). Cases with concurrent expression of MYC and BCL2 showed a lower OS, although the difference did not reach statistical significance. Translocations involving the MYC or BCL2 genes were not detected. The BCL6 gene was frequently translocated, but was unrelated to survival. We conclude that MYC protein expression detected by immunohistochemistry identifies a CNS-DLBCL subset with worse prognosis and may contribute to a more accurate risk stratification of CNS-DLBCL patients.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BCL2; MYC; immunohistochemistry; primary CNS lymphoma; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26010683     DOI: 10.1111/apm.12390

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  10 in total

1.  BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Keishi Makino; Hideo Nakamura; Naoki Shinojima; Jun-Ichiro Kuroda; Shigetoshi Yano; Yoshiki Mikami; Akitake Mukasa
Journal:  J Neurooncol       Date:  2018-07-02       Impact factor: 4.130

2.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 3.  Advances in Pathobiology of Primary Central Nervous System Lymphoma.

Authors:  Xue-Liang Yang; Yuan-Bo Liu
Journal:  Chin Med J (Engl)       Date:  2017-08-20       Impact factor: 2.628

4.  Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report.

Authors:  Appalanaidu Sasapu; Dinesh Atwal; Giovanni Insuasti-Beltran; Yogesh Jethava
Journal:  Blood Res       Date:  2018-03-27

5.  Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.

Authors:  Yangying Zhou; Zhijie Xu; Wei Lin; Yumei Duan; Can Lu; Wei Liu; Weiping Su; Yuanliang Yan; Huan Liu; Li Liu; Meizuo Zhong; Jianhua Zhou; Hong Zhu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

Review 6.  Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.

Authors:  Marietya I S Lauw; Calixto-Hope G Lucas; Robert S Ohgami; Kwun Wah Wen
Journal:  Diagnostics (Basel)       Date:  2020-12-11

Review 7.  Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.

Authors:  Walter Douglas Fairlie; Erinna F Lee
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

8.  Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.

Authors:  Jinuk Kim; Tae Gyu Kim; Hyoun Wook Lee; Seok Hyun Kim; Ji Eun Park; Moonok Lee; Young Zoon Kim
Journal:  Curr Oncol       Date:  2021-11-12       Impact factor: 3.677

9.  Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial.

Authors:  Jingjing Wu; Fenghua Gao; Wenhua Wang; Xudong Zhang; Meng Dong; Lei Zhang; Xin Li; Ling Li; Zhenchang Sun; Xinhua Wang; Xiaorui Fu; Linan Zhu; Mengjie Ding; Songtao Niu; Zhaoming Li; Yu Chang; Feifei Nan; Jiaqian Yan; Hui Yu; Xiaolong Wu; Zhiyuan Zhou; Jieming Zhang; Mingzhi Zhang
Journal:  Cancer Biol Med       Date:  2021-10-12       Impact factor: 5.347

10.  MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Dohee Kwon; Hannah Kim; Eunyoung Lee; Tae Min Kim; Dae Seog Heo; Sung Hye Park; Chul Woo Kim; Yoon Kyung Jeon
Journal:  BMC Cancer       Date:  2016-06-10       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.